TARA Stock Risk & Deep Value Analysis
Protara Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About TARA Stock
We analyzed Protara Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TARA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TARA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the potential clinical trial failure of TARA-002 for refractory lymphatic malformations, or an unfavorable regulatory decision, which would jeopardize the company's primary asset. This could lead to a substantial loss of the current $177.4 million cash and investments, requiring significant additional capital raises through dilution or asset sales, potentially rendering current equity nearly worthless without a revenue-generating product.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Widened net loss of $(17.8M) in Q1 2026, representing a +49.6% YoY increase, indicates an accelerating cash burn rate.
- ⚠
Filing of a $300M shelf registration on May 14, 2026, explicitly signals a high likelihood of significant future equity dilution to fund operations.
- ⚠
BLA submission for the lead asset, TARA-002, is not planned until 2H 2027, extending the period of cash burn before potential revenue generation.
Upcoming Risk Events
- 📅
Phase 3 trial failure for TARA-002 in Lymphatic Malformations (results anticipated in late 2026 / early 2027): Would be a catastrophic event, likely leading to significant stock price decline.
- 📅
Significant dilution from the $300M shelf registration (ongoing into 2H 2026 and 2027): Could materially reduce per-share value if executed at current low prices.
When to Reconsider
- 🚪
Exit if TARA-002 Phase 3 trial results (expected late 2026/early 2027) for lymphatic malformations are negative or inconclusive.
- 🚪
Sell if cash and investments fall below $50M without a clear, non-dilutive financing plan, indicating immediate liquidity distress.
- 🚪
Exit if shares outstanding increase by more than 50% due to dilution (from shelf registration) without a corresponding positive clinical or regulatory milestone.
Unlock TARA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Protara Therapeutics Inc (TARA) Do?
Market Cap
$276.52M
Sector
Healthcare
Industry
Biotechnology
Employees
28
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Visit Protara Therapeutics Inc WebsiteInvestment Thesis
If Protara Therapeutics successfully submits its BLA for TARA-002 in lymphatic malformations in 2H 2027 and subsequently gains FDA approval, leveraging its Orphan Drug and Breakthrough Therapy designations, then the company could achieve peak annual sales of $500M-$1B. This would justify a market re-rating to $1.5B-$3B, representing a 5x-10x return on its current $0.28B market cap, as the market is currently heavily discounting the probability of clinical and regulatory success due to the binary risk and significant future funding requirements.
Is TARA Stock Undervalued?
Unlock the full AI analysis for TARA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TARA Price Targets & Strategy
12-Month Target
$26.25
Bull Case
$49.20
Bear Case
$1.00
Valuation Basis
Based on analyst consensus average, which likely incorporates risk-adjusted net present value (rNPV) of TARA-002's potential orphan drug peak sales.
Entry Strategy
Given the high-risk profile, consider dollar-cost averaging on dips towards $4.00-$4.50 (recent support zone) after positive clinical updates.
Exit Strategy
Take profit at $26.25 (average analyst target); Stop loss at $2.50 (if TARA-002 clinical outlook deteriorates significantly).
Portfolio Allocation
3% for aggressive risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TARA Financially Healthy?
Valuation
P/E Ratio
-3.64
Price/Book
0.78
Profitability
Return on Equity
-38.70%
EPS
$-1.35
Balance Sheet
Current Ratio
14.58
Quick Ratio
14.34
Total Debt
$3.95M
Cash & Equivalents
$122.22M
Cash Flow
Operating Cash Flow
-$44.71M
Free Cash Flow
-$44.78M
Other
Beta (Volatility)
1.50
Does TARA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability is contingent on the successful clinical development and regulatory approval of TARA-002. If approved, regulatory exclusivity and patent protection would provide a strong, albeit time-limited, barrier to competition.
Moat Erosion Risks
- •Clinical failure of TARA-002 would entirely erode the company's current competitive advantage and primary value proposition.
- •Emergence of superior alternative therapies or treatment modalities from competitors could diminish TARA-002's market potential even if approved.
TARA Competitive Moat Analysis
Sign up to see competitive advantages
TARA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Limited retail investor data available, but typically speculative for clinical-stage biotechs)
Institutional Sentiment
Positive (71.78% institutional ownership, 75% Buy / 25% Strong Buy analyst consensus)
Insider Activity (Form 4)
No recent Form 4 transactions were provided in the supplied sources within the last 90 days for CEO/CFO buying or selling.
Options Flow
Normal options activity (No specific unusual options activity or put/call ratio direction was provided in the sources.)
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium (Q1 2026 EPS beat estimates, but forecasting for pre-revenue biotechs is challenging)
Historical Earnings Pattern
Insufficient data to establish a consistent historical pattern; price volatility is common around clinical and regulatory updates.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No specific competitor named in research; competition varies by indication)
Market Share Trend
Not applicable for a clinical-stage company; market share is zero. Aiming to gain significant share in niche orphan disease markets upon approval.
Valuation vs Peers
Trading at a significant discount on Price/Book (0.7x vs. sector average 2.5x), typical for a pre-revenue, high-risk biotech where future success is heavily discounted.
Competitive Advantages
- •FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations, granting potential market exclusivity.
- •FDA Breakthrough Therapy and Fast Track Designations for TARA-002, accelerating development and review processes.
- •Proprietary IP surrounding TARA-002 as a therapeutic agent.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TARA Stock Higher?
Near-Term (0-6 months)
- •THRIVE-3 interim data for TARA-002 in NMIBC in 2H 2026: Positive results could validate broader potential of TARA-002 beyond LMs.
- •Completion of ADVANCED-2 cohort enrollment and initiation of ADVANCED-3 in 2H 2026: Signals progress in NMIBC program development.
Medium-Term (6-18 months)
- •BLA submission for TARA-002 in lymphatic malformations in 2H 2027: A successful submission is a major regulatory milestone and de-risks the path to market.
- •FDA approval decision for TARA-002 in lymphatic malformations (estimated 1H 2028): Grants market access, transforming the company from clinical to commercial stage.
Long-Term (18+ months)
- •Commercial launch of TARA-002 for LMs (estimated 2H 2028): If successful, peak annual sales could reach $500M-$1B, re-rating market cap to $1.5B-$3B.
- •Expansion of TARA-002 into the larger non-muscle invasive bladder cancer (NMIBC) market: Represents a significant expansion of TAM and revenue potential post-LMs approval.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TARA?
- ✓
Watch quarterly net loss and cash burn rate for any acceleration beyond Q1 2026's $(17.8M) to gauge financial runway.
- ✓
Monitor official announcements regarding the completion of ADVANCED-2 enrollment and interim THRIVE-3 data in 2H 2026 for positive clinical momentum.
Bull Case Analysis
Sign up free to see the bull case
Competing with TARA
See how Protara Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Protara Therapeutics Inc TARA | $276.5M | 4.5 | -3.6 | — | — | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Protara Therapeutics Inc Makes Money
Protara Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare and specialty diseases. Its primary product candidate, TARA-002, is currently in clinical trials for two main indications: refractory lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). The company does not currently generate revenue from product sales, relying instead on raising capital through equity offerings to fund its research and development activities and operational expenses. Its business model relies entirely on the successful clinical development, regulatory approval, and eventual commercialization of TARA-002 or other pipeline candidates.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Protara Therapeutics Inc (TARA)?
As of May 25, 2026, Protara Therapeutics Inc has a DVR Score of 4.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Protara Therapeutics Inc?
Protara Therapeutics Inc's market capitalization is approximately $276.5M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Protara Therapeutics Inc use?
TARA is the ticker symbol for Protara Therapeutics Inc. The company trades on the NGM.
What is the risk level for TARA stock?
Our analysis rates Protara Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TARA?
Protara Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -3.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the TARA DVR analysis updated?
Our AI-powered analysis of Protara Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TARA (Protara Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.